The efficacy and safety of ginkgo terpene lactone preparations combined with antiplatelet aents in the treatment of ischemic stroke: a systematic review and meta-analysis

source extracted confidence: high 2026-04-09

The efficacy and safety of ginkgo terpene lactone preparations combined with antiplatelet aents in the treatment of ischemic stroke: a systematic review and meta-analysis

Xu et al., 2025 | Front Pharmacol | Systematic Review

Citation

Xu Hong, Zeng Li, ... Tang Yan. The efficacy and safety of ginkgo terpene lactone preparations combined with antiplatelet aents in the treatment of ischemic stroke: a systematic review and meta-analysis. Front Pharmacol. 2025;16:1554207. doi:10.3389/fphar.2025.1554207

Abstract

BACKGROUND: This meta-analysis aimed to assess the efficacy and safety of ginkgo terpene lactone preparations including diterpene ginkgolides meglumine injection (DGMI) and ginkgolide injection combined with antiplatelet drugs in the treatment of ischemic stroke. METHODS: We systematically searched the randomized controlled trials(RCTs) with publication date earlier than 6 November 2024 in PubMed, China National Knowledge Infrastructure (CNKI), Chinese Science and Technology Journal Database (VIP), Chinese Biomedical Literature Database (CBM), Wanfang Database, Embase, Web of Science, ClinicalTrials.gov, and Cochrane Library. Studies were screened according to inclusion and exclusion criteria, evaluated according to criteria recommended by the Cochrane Handbook, and data were then analyzed using Stata 17 software. RESULTS: Of 1,079 identified studies, 27 were eligible and included in our analysis (N = 3,336 patients). The meta-analysis demonstrated that the overall response rate [RR = 1.22, 95% CI(1.17, 1.27), Z = 9.76, p < 0.01], as well as the National Institutes of Health Stroke Scale (NIHSS) score and barthel index, were significantly better in the DGMI combined treatment group compared to the antiplatelet therapy alone group. However, there was no significant difference observed between the experimental group and the control group regarding improvements in prognosis and platelet function. The studies included in the analysis reported a total of 419 adverse reactions (ADRs), with 206 occurring in the DGMI combined treatment group; furthermore, there was no significant difference in the incidence of adverse events between the two groups. CONCLUSION: Ginkgo terpene lactone preparations, when combined with antiplatelet drugs, can significantly enhance the clinical efficacy of ischemic stroke and demonstrate a favorable safety profile. This combination is a potential treatment strategy that can improve the management of IS patients and has high clinical application value.

Key Findings

Of 1,079 identified studies, 27 were eligible and included in our analysis (N = 3,336 patients). The meta-analysis demonstrated that the overall response rate [RR = 1.22, 95% CI(1.17, 1.27), Z = 9.76, p < 0.01], as well as the National Institutes of Health Stroke Scale (NIHSS) score and barthel index, were significantly better in the DGMI combined treatment group compared to the antiplatelet therapy alone group. However, there was no significant difference observed between the experimental group

Outcomes Measured

  • Requires manual extraction

Population

Field Value
Population See abstract
Sample Size 3336
Age Range See abstract
Condition See abstract

MeSH Terms

  • No MeSH terms indexed

Evidence Classification

  • Level: Systematic Review
  • Publication Types: Journal Article, Systematic Review
  • Vertical: ginkgo

Provenance

Source extracted via PubMed E-utilities API on 2026-04-09